Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

ion or $0.32 per share.

As of September 30, 2008, the Company held cash, cash equivalents and investments of $67.9 million.

Year-to-Date 2008 Financial Results

Collaborative and other research and development revenues were $22.3 million for the nine months ended September 30, 2008, compared to $43.1 million for the nine months ended September 30, 2007. This decrease is driven by a reduction in peramivir related clinical development costs leading to a reduction in costs and associated revenue from HHS, plus the $4.9 million reserve taken in the second quarter of 2008 for amounts BioCryst previously expected to receive from HHS related to costs incurred in the Phase 3 program in intramuscular peramivir for outpatient influenza. These costs were associated with the Phase 3 program for peramivir that was voluntarily discontinued earlier this year and reimbursement of these costs is under discussion with HHS.

R&D expenses were $51.3 million for the nine months ended September 30, 2008, compared to $64.9 million for the nine months ended September 30, 2007. The decrease in R&D expenses is due to a reduction in the clinical development costs and toxicology costs associated with the peramivir program and a reduction in manufacturing costs associated with both the peramivir and forodesine HCl programs. These reductions were partially offset by an increase in the Company's clinical development costs for forodesine HCl and increases in personnel related costs and professional services.

G&A expenses were $8.0 million for the nine months ended September 30, 2008, compared to $7.0 million for the nine months ended September 30, 2007. The higher expenses were primarily due to an increase in professional fees and personnel related costs.

The net loss for the nine months ended September 30, 2008 was $34.8 million, or $0.91 per share, compared to a net loss for the nine months ended September 30, 2007 of $26.8 million or $0.86 per share.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... N.J., Nov. 13 Soligenix, Inc., (Soligenix or ... as DOR BioPharma, Inc., a late-stage biotechnology company, ... quarter of 2009. , Highlights and ... enrollment in its confirmatory Phase 3 randomized, double-blind, ...
... ... System that addresses common problems associated with purification of recombinant proteins by enabling ... , ... Madison, WI (PRWEB) November 12, 2009 -- The recently released Promega HaloTag® Protein ...
... Exchange Symbol: MS , EDMONTON, Nov. 12 /PRNewswire-FirstCall/ - ... operational results for the three and nine months ended ... license and collaboration agreement between BioMS Medical and Eli ... with the effect that all commercial rights to dirucotide ...
Cached Biology Technology:Soligenix Reports Third Quarter 2009 Financial Results 2Soligenix Reports Third Quarter 2009 Financial Results 3Soligenix Reports Third Quarter 2009 Financial Results 4Soligenix Reports Third Quarter 2009 Financial Results 5Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins 2BioMS Medical Announces Third Quarter 2009 Results 2BioMS Medical Announces Third Quarter 2009 Results 3BioMS Medical Announces Third Quarter 2009 Results 4BioMS Medical Announces Third Quarter 2009 Results 5BioMS Medical Announces Third Quarter 2009 Results 6BioMS Medical Announces Third Quarter 2009 Results 7BioMS Medical Announces Third Quarter 2009 Results 8
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... available in Spanish . Studies by ... presence of Escherichia coli pathogens in surface waters ... in underwater sediments. Most E. coli strains ... water quality managers to estimate fecal contamination. These findings, ...
... of years ago, humans discovered flammable gas could be produced ... anaerobic digestion. Today, EU laws are pushing governments to use ... to enrich soil or biogas for energy. Our environment would ... dumped in diminishing landfill sites. However, while the scientific ...
... have filled an important gap in the study of tunicate ... gelatinous, free-swimming types of tunicates. Their study was featured on ... of Plankton Research . Tunicates are a phylum of ... covering called a tunic, from which the name derives. ...
Cached Biology News:E. coli can survive in streambed sediments for months 2Time to make more out of waste 2Time to make more out of waste 3Woods Hole Oceanographic Institution study sheds light on tunicate evolution 2
... for 25 chips provides the chips and ... (at nanogram levels) with the Experion automated ... StdSens microfluidic chips, 2 x 1,250 microliters ... StdSens stain, 2 x 20 microliters RNA ...
...
... System is a full featured, two laser, six ... Flow Cytometer, CFlow Software, and a PC for ... provides all the capabilities of the best selling ... The C6 Flow Cytometer System has six detectors ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: